Our research

---

• Initial Validation: Informuta's ML models have undergone extensive preclinical validation on patient samples of Pseudomonas aeruginosa from chronic lung infections, achieving a 100% accuracy rate in predicting the resistance-prone phenotype (6). 
• Retrospective Cohorts: Validated models using four independent retrospective cohorts of patient samples with an average accuracy rate of 92% (6). 

• We are commencing prospective clinical studies in late Fall 2024 in collaboration with 5 leading healthcare institutions.

At Informuta, we are committed to advancing the scientific understanding of bacterial mutagenesis, antibiotic resistance mechanisms, and bacterial evolution. Our innovative diagnostic technology offers bench researchers an unprecedented opportunity to explore these areas with greater depth and precision.

Our technology doesn't just identify resistance; it predicts its future path, providing a dynamic view of how bacterial populations evolve under drug pressure. This predictive capability opens new avenues for investigating the underlying genetic and biochemical mechanisms that drive resistance. Additionally, our models serve as a rapid functional assay to determine specific resistance phenotypes and DNA replication and repair pathway activities, using sequencing data alone. 

RESISENSE™ by Informuta is an advanced diagnostic platform designed to empower clinicians in the battle against antibiotic-resistant infections. By leveraging next-generation sequencing (NGS) and proprietary machine learning (ML) models, RESISENSE™ delivers rapid and precise genomic antibiotic susceptibility testing (g-AST), enabling clinicians to make informed treatment decisions within 24 hours. This platform not only detects current antibiotic resistance, but also predicts future resistance acquisition for the very first time. 

For healthcare providers, RESISENSE™ can serve as an incredibly powerful tool in improving patient outcomes, promoting antibiotic stewardship, and managing and preventing emergence and spread of drug-resistant infections.